FASEB SRC on Molecular, Structural & Clinical Aspects of Vitamin K & Vitamin K-dependent Proteins

 描述(由申请人提供)：维生素K(VK)因其止血作用而被发现，历史上所需的维生素K是基于正常凝血所需的量。在过去，VK领域的凝聚力在很大程度上是通过关注止血来维持的。然而，VK领域现在已经超越了这一焦点，并且正在由VK领域的新手积极地跨高度不同的学科进行研究。科学相互作用已变得越来越具有挑战性，因为VK生物学不再由一个单一的科学协会代表。2015年FASE B关于VK和VK依赖蛋白的分子、结构和临床方面的夏季会议对该领域具有重要意义，因为这是唯一致力于VK生物学研究的国家和/或国际会议。本次会议的总体目标是为交流有关VK的新知识提供一个论坛，从基础研究到广泛的临床应用。考虑到这一独特的和高度学科的主题，我们的总体会议目标是：(1)包括与VK相关的主题的公认的多学科专家；(2)在年轻和有经验的研究人员中讨论该领域的重大进展，包括那些基于传统上与VK社区无关的学科的研究人员；以及(3)确保新想法和新研究人员的持续涌入。为了实现这一目标，我们创建了一个由许多演讲者组成的项目，他们将首次与VK社区互动。我们还纳入了研究生和研究生实习生以及初级科学家与现有研究人员互动的多种机会，以促进VK领域的新一批调查人员。2015年大会将讨论的科学问题反映了VK生物学的这种翻译性质：(1)从基础和临床研究角度评估当前对VK代谢及其独特作用的研究；(2)促进我们当前对华法林、直接口服抗凝剂(DOAC)和药物基因组信息的使用的知识，以开发相关凝血障碍的最佳治疗和预防；(3)评估VK依赖蛋白在管理心血管疾病、骨关节炎和慢性肾脏疾病等临床疾病中新出现的作用的新进展；以及(4)促进对VK环氧化物还原酶(VKOR)的理解。这次会议具有创新性，因为它将利用细胞生物学、生物化学、内分泌学、肾病学、血液学和营养学等基础科学和临床领域中公认的主席和演讲者的多学科专业知识，就VK的新联系和作用进行讨论，并将 促进新的合作和新的研究领域。

 DESCRIPTION (provided by applicant): Vitamin K (VK) was discovered for its role in hemostasis, and requirements were historically based on the amount required for normal blood coagulation. In the past, the cohesiveness of the VK field was largely maintained by the focus on hemostasis. However, the field of VK now extends beyond this focus and is actively being studied across highly diverse disciplines by investigators new to the VK field. Scientific interactions have become increasingly challenging because VK biology is no longer represented by a single scientific society. The 2015 FASEB Summer Conference on "Molecular, Structural & Clinical Aspects of VK & VK-Dependent Proteins" is significant to the field because it is the only national and/or international conference dedicated to the study of VK biology. The overall objective of this conference is to provide a forum for the exchange of new knowledge about VK that spans from basic research to a wide variety of clinical applications. In recognition of this unique and highly disciplinary theme, our overarching conference goals are to: (1) Feature recognized multidisciplinary experts covering topics related to VK; (2) Discuss major advances in the field among young and experienced investigators, including those who are based in disciplines not traditionally associated with the VK community; and (3) Ensure a continued influx of new ideas and new investigators. To achieve this, we have created a program composed of many speakers who will be interacting with the VK community for the first time. We have also incorporated multiple opportunities for the interaction of graduate and post-graduate trainees and junior scientists with established investigators to promote a new cadre of investigators in the field of VK. The scientific problems to be discussed at the 2015 conference reflect this translational nature of VK biology: (1) Evaluate current research on VK metabolism and its unique actions both from basic and clinical research perspectives; (2) Advance our current knowledge on the use of warfarin, direct oral anticoagulants (DOACs), and pharmacogenomic information to develop optimal treatment and prevention of associated coagulopathy; (3) Evaluate new developments that suggest emerging roles for VK-dependent proteins in managing clinical conditions such as CVD, osteoarthritis, and chronic kidney disease; and (4) Advance the understanding VK epoxide reductase (VKOR). This conference is innovative because it will provide discussion on new linkages and roles of VK by drawing on the multi-disciplinary expertise of confirmed chairpersons and speakers in the basic science and clinical fields of cell biology, biochemistry, endocrinology, nephrology, hematology and nutrition, and will facilitate new collaborations and areas of novel research.